Angiogenesis-related lncRNAs index: A predictor for CESC prognosis, immunotherapy efficacy, and chemosensitivity

TL;DR

This study identifies a set of long non-coding RNAs linked to blood vessel growth that can predict cervical cancer outcomes and treatment response.

Contribution

A novel angiogenesis-related lncRNA signature for CESC prognosis and immunotherapy prediction is developed.

Findings

Seven angiogenesis-related lncRNAs were identified as prognostic markers for CESC.

The signature correlates with immune cell infiltration and drug sensitivity in CESC.

A nomogram combining the signature and clinical features improves prediction accuracy.

Abstract

Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) is a common gynecologic tumor and patients with advanced and recurrent disease usually have a poor clinical outcome. Angiogenesis is involved in the biological processes of tumors and can promote tumor growth and invasion. In this paper, we created a signature for predicting prognosis based on angiogenesis-related lncRNAs (ARLs). This provides a prospective direction for enhancing the efficacy of immunotherapy in CESC patients. We screened seven OS-related ARLs by univariate and multivariate regression analyses and Lasso analysis and developed a prognostic signature at the same time. Then, we performed an internal validation in the TCGA-CESC cohort to increase the precision of the study. In addition, we performed a series of analyses based on ARLs, including immune cell infiltration, immune function, immune checkpoint, tumor mutation load, and drug sensitivity analysis. Our created signature based on ARLs can effectively predict the prognosis of CESC patients. To strengthen the prediction accuracy of the signature, we built a nomogram by combining signature and clinical features.

Figures